Takeaways: The Canadian approval expands Epkinly into a second major lymphoma indication (after DLBCL), giving AbbVie a bispecific‑based triplet option in relapsed/refractory follicular ly...
Takeaways: Approval would position Jemperli as a potential first‑line, organ‑preserving immunotherapy for dMMR/MSI‑H locally advanced rectal cancer, opening a new, biomarker‑defined segment with...
Takeaways: Signia’s Multi‑adaptive Xperience (MaX) launch in Canada brings an AI‑driven, four‑DNN platform (speech, noise, environment, own‑voice) that the company says is the first of its kind ...
Takeaways: Health Canada’s approval of Imcivree (setmelanotide) for acquired hypothalamic obesity (HO) gives Rhythm Pharmaceuticals its first targeted therapy in Canada for this rare, injury‑dri...
Takeaways: Blair Health’s CAD $4.24M pre‑seed raise (total CAD $4.5M) gives it the capital to scale a “virtual specialist” model that encodes specialist‑designed pathways into software so genera...
Abbott’s Volt PFA System Debuts in Canada Abbott announced the first Canadian use of its Volt Pulsed Field Ablation (PFA) System at McGill University Health Centre in Montreal to treat patients with a...
Takeaways: Health Canada’s authorization of the XFG‑adapted Comirnaty vaccine for the 2026–2027 season keeps Pfizer/BioNTech aligned with national recommendations to match contemporary Omicron l...
Takeaways: Sandoz Canada’s Health Canada authorization for PrSandoz Semaglutide, a generic version of Ozempic, gives the country its first lower‑cost semaglutide option for type 2 diabetes...
Takeaways: Sanofi’s new Charles Best Building in Toronto adds end‑to‑end flu vaccine manufacturing capacity in Canada and is set to become the central hub for producing Fluzone High‑Dose for adu...
Takeaways: Optimi Health’s plan to start a Health Canada‑authorized Phase 3 trial of synthetic MDMA‑assisted therapy for PTSD in 2027 positions the company to potentially become an early mover i...